vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
zitromax 500 mg pulver til koncentrat til infusionsvæske, opløsning
nordic prime aps - azithromycindihydrat - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
diflucan 150 mg kapsler, hårde
pfizer aps - fluconazol - kapsler, hårde - 150 mg
diflucan 200 mg kapsler, hårde
pfizer aps - fluconazol - kapsler, hårde - 200 mg
flucobeta 100 mg kapsler, hårde
teva pharma b.v. - fluconazol - kapsler, hårde - 100 mg
flucobeta 150 mg kapsler, hårde
teva pharma b.v. - fluconazol - kapsler, hårde - 150 mg
flucobeta 200 mg kapsler, hårde
teva pharma b.v. - fluconazol - kapsler, hårde - 200 mg
flucobeta 50 mg kapsler, hårde
teva pharma b.v. - fluconazol - kapsler, hårde - 50 mg
flucoglan 150 mg kapsler, hårde
gedeon richter plc. - fluconazol - kapsler, hårde - 150 mg
flucoglan 200 mg kapsler, hårde
gedeon richter plc. - fluconazol - kapsler, hårde - 200 mg